Threshold Pharmaceuticals (THLD) Reports Positive Clinical Trials of TH-302 for Solid Tumors
Tweet Send to a Friend
Threshold Pharmaceuticals, Inc. (Nasdaq: THLD) previously announced on May 30, 2009, clinical trial results related to its clinical stage hypoxia-activated ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
